Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
The GLP-1s were all initially done for type two diabetes, Dr
CagriSema's Advantages: First to Market: 6-12 month head start Leverages Wegovy Success: Built-in brand recognition Proven Semaglutide Component: Half the drug is already approved Strong Diabetes Data: Positions for dual indication No Dysesthesia: Cleaner safety profile in one key area Retatrutide's Advantages: Higher Efficacy: 28.7% vs 20.4% (8.3 points more) Superior BP Reduction: -14 mmHg vs likely similar to semaglutide Single Molecule: Potentially easier manufacturing Multiple Indications: OA, OSA, obesity, diabetes trials Novel Class: First triple agonist = strong IP protection The Verdict: Market Will Support Both These medications won't compete head-to-head
Mean body weight at randomization (Week 20) was 96.1 kg and mean BMI at randomization (Week 20) was 34.4 kg/m2
GLP-1 medication can also put people at risk of developing: thyroid tumors, including cancer acute pancreatitis gallbladder injury acute kidney injury vision problems diabetic retinopathy The price people pay for GLP-1 pills will depend on their health insurance and whether they are eligible for any savings programs
Common choices include: 1ml 2ml 5ml Custom Values Concentration is the key
US$ 20.61
US$ 27.27
US$ 24.35
US$ 22.23
US$ 27.87
US$ 27.15
